

Teruhiko Tanabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3291159/publications.pdf>

Version: 2024-02-01

9
papers

101
citations

1684188
5
h-index

1588992
8
g-index

12
all docs

12
docs citations

12
times ranked

167
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictive value of the Hyodo score in endoscopic evaluation of aspiration during swallowing. <i>Auris Nasus Larynx</i> , 2018, 45, 1214-1220.	1.2	37
2	Lymph node ratio as a prognostic factor for survival in patients with head and neck squamous cell carcinoma. <i>Auris Nasus Larynx</i> , 2018, 45, 846-853.	1.2	19
3	The applicability of new TNM classification for humanpapilloma virus-related oropharyngeal cancer in the 8th edition of the AJCC/UICC TNM staging system in Japan: A single-centre study. <i>Auris Nasus Larynx</i> , 2018, 45, 558-565.	1.2	18
4	Efficacy and safety of postoperative bio-chemoradiotherapy using cetuximab and docetaxel for high-risk head and neck cancer patients in Japan. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 80, 203-207.	2.3	9
5	A prospective clinical trial of the second-look procedure for transoral surgery in patients with T1 and T2 laryngeal, oropharyngeal, and hypopharyngeal cancer. <i>Cancer Medicine</i> , 2019, 8, 7197-7206.	2.8	8
6	The Second-Look Procedure for Transoral Videolaryngoscopic Surgery for T1 and T2 Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer Patients: Protocol for a Nonrandomized Clinical Trial. <i>JMIR Research Protocols</i> , 2017, 6, e235.	1.0	5
7	Postoperative Bio-Chemoradiotherapy Using Cetuximab and Docetaxel in Patients With Cis-Platinum-Intolerant Core High-Risk Head and Neck Cancer: Protocol of a Phase 2 Nonrandomized Clinical Trial. <i>JMIR Research Protocols</i> , 2018, 7, e11003.	1.0	3
8	Addition of S-1 to radiotherapy for treatment of T2N0 glottic cancer: Results of the multiple-center retrospective cohort study in Japan with a propensity score analysis. <i>Oral Oncology</i> , 2019, 99, 104454.	1.5	2
9	Lymph node ratio as a prognostic factor for survival in patients with head and neck squamous cell carcinoma. <i>Journal of Otolaryngology of Japan</i> , 2019, 122, 1009-1010.	0.1	0